
    
      OBJECTIVES:

      I. Determine the response rate to docetaxel in children with recurrent sarcomas,
      neuroblastomas, or brain tumors.

      II. Describe the toxic effects of docetaxel in these patients.

      OUTLINE:

      All patients receive docetaxel with G-CSF every 21 days for up to 12 courses. Patients are
      followed for survival.
    
  